Demetrix Begins CBG sampling for Health & Wellness
Biotechnology company using fermentation to create rare cannabinoids begins delivering samples up to tens of grams, allowing skincare and consumer products companies to begin formulation work
BERKELEY, Calif – November 10, 2020 – Demetrix Inc., a biotechnology company that makes safe, legal and effective cannabinoids, today announced that it has launched a sampling program for the rare cannabinoid cannabigerol (CBG). The program makes CBG available in samples up to tens of grams to companies developing skincare, pharmaceutical, and other health and wellness products using cannabinoids. The program follows the company’s recent successful 15,000-liter demo scale production of CBG earlier this year.
There is a massive commercial market for common cannabinoids like CBD, which is found in high concentrations in cannabis and hemp plants. However, rare cannabinoids like CBG, which show promise for a range of benefits, are typically found in quantities below one percent in the plant, making them impossible to access, study, and use. Demetrix has created an industry-leading fermentation technology platform that allows the company to produce rare cannabinoids like CBG faster, more sustainably, at greater purity, and more affordably than traditional methods.
“We’re excited to get samples of CBG into the hands of innovative companies that are creating the next generation of products using cannabinoids.”
— Chief Commerical Officer, Cindy Bryant
“Demetrix believes in the power of science to make the world a better place,” said Cindy Bryant, Chief Commercial Officer at Demetrix. “Our fermentation platform allows us to produce highly pure CBG that is always THC-free, and our foundational research shows CBG has promising skin health applications due to its antioxidant and anti-inflammatory performance. With the intense interest in cannabinoids and the promising performance for skin health, we expect CBG to have strong consumer imagery and marketing potential. We’re excited to get samples of CBG into the hands of innovative companies that are creating the next generation of products using cannabinoids.”
Demetrix is a venture-backed company that has secured $61 million dollars to date. The company’s team is made up of industry veterans with a long history of innovation and bringing fermentation products to market, with experts in R&D, production, regulation, and commercialization.
Demetrix is a biotechnology company that believes in the power of science to make the world a better place. The company produces health and wellness products backed by science, including rare, high-purity cannabinoids for pharmaceutical and consumer applications. Demetrix has a team of industry-leading experts across R&D, production, regulation, and commercialization, with deep experience bringing fermentation products to market. The company is pioneering the study of the more than 100 rare cannabinoids and their interactions with the human body. Demetrix has secured $61 million in venture-led funding and is based in Berkeley, California.
FOR MORE INFORMATION: